Login
$HROW
$28.94 -$0.02 (0.05%) Live

Company Executives

$HROW Management Team

Mr. Andrew Boll

President

Chief Financial Officer

Company Secretary

Age 42
Compensation $849.2K USD
Sex Male

Mr. Frank Mullery

Chief Executive Officer of ImprimisRx

Age -
Compensation -
Sex Male

Mr. Randall Pollard

Chief Accounting Officer

Age 53
Compensation -
Sex Male

Mr. Amir Shojaei

Chief Scientific Officer

Age 57
Compensation -
Sex Male

Mr. Mark Baum

Chairman of the Board

Chief Executive Officer

Age 52
Compensation $1.358M USD
Sex Male

Mr. Patrick Sullivan

Chief Commercial Officer

Age -
Compensation -
Sex Male
Directors
4
serving now
Independent
3 of 4
stated in the proxy
Average tenure
5.8 years
from year joined
CEO also chairs the board
Yes
Mark L. Baum
Director Age On board Independent Committees Other public boards 2025 pay Source
Mark L. Baum
53 2011
15 years
Not independent None stated None stated Paid as CEO
Adrienne L. Graves
72 2024
2 years
Independent
Audit Committee Compensation Committee · Chair Nomination and Corporate Governance Committee · Chair
Ocular Therapeutix, Inc., Opus Genetics, Inc. $308,764
Lauren P. Silvernail
67 2024
2 years
Independent
Audit Committee · Chair Compensation Committee
None stated $307,514
Perry J. Sternberg
57 2022
4 years
Independent
Audit Committee Compensation Committee Nomination and Corporate Governance Committee
None stated $327,514

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 24, 2026
Perry J. Sternberg
director of the Company, currently a director of Surface
Amount not stated

Company holds 3,500,000 common shares of Surface (about 20%), accounted for under the equity method; carrying value reduced to zero.

With Surface Ophthalmics, Inc. Open in proxy
Mark L. Baum
Chief Executive Officer of the Company
Approximately $428,000
2025

Harrow's acquisition of remaining equity interests in Melt; Mr. Baum held Melt equity and received cash at closing.

With Melt Pharmaceuticals, Inc. Open in proxy
Andrew R. Boll
Chief Financial Officer of the Company
Approximately $204,000
2025

Harrow's acquisition of remaining equity interests in Melt; Mr. Boll held Melt equity and received cash at closing.

With Melt Pharmaceuticals, Inc. Open in proxy
John P. Saharek
former Chief Executive Officer of ImprimisRx; held equity interests in Melt
Approximately $10,000
2025

Harrow's acquisition of remaining equity interests in Melt; Mr. Saharek held Melt equity, received cash at closing and is entitled to contingent consideration.

With Melt Pharmaceuticals, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support